Literature DB >> 20410531

Prevalence, pathogenesis, and impact of atrial fibrillation.

Cynthia A Sanoski1.   

Abstract

PURPOSE: To describe the prevalence, pathophysiology, and consequences of atrial fibrillation (AF) and the risk factors for the rhythm disturbance.
SUMMARY: The prevalence of AF, a common age-related disorder that causes substantial morbidity and mortality, is increasing. Structural heart disease (e.g., coronary heart disease, hypertension, heart failure, valvular heart disease) is a common comorbidity of and risk factor for AF, although various other factors have been shown to play a role in the pathogenesis of this disorder. The risk for AF and ischemic stroke, a major complication of AF, can be estimated using risk-scoring systems. The rate of hospitalization for AF and the costs of treating AF are increasing in the United States.
CONCLUSION: Understanding the pathogenesis of and risk factors for AF and using risk-scoring systems to estimate the risk for AF and stroke can facilitate treatment of this rhythm disorder and potentially minimize its morbidity, mortality, and costs.

Entities:  

Mesh:

Year:  2010        PMID: 20410531     DOI: 10.2146/ajhp100148

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  7 in total

1.  Relation of serum phosphorus levels to the incidence of atrial fibrillation (from the Atherosclerosis Risk In Communities [ARIC] study).

Authors:  Faye L Lopez; Sunil K Agarwal; Morgan E Grams; Laura R Loehr; Elsayed Z Soliman; Pamela L Lutsey; Lin Y Chen; Rachel R Huxley; Alvaro Alonso
Journal:  Am J Cardiol       Date:  2012-12-28       Impact factor: 2.778

2.  Blood lipid levels, lipid-lowering medications, and the incidence of atrial fibrillation: the atherosclerosis risk in communities study.

Authors:  Faye L Lopez; Sunil K Agarwal; Richard F Maclehose; Elsayed Z Soliman; A Richey Sharrett; Rachel R Huxley; Suma Konety; Christie M Ballantyne; Alvaro Alonso
Journal:  Circ Arrhythm Electrophysiol       Date:  2012-01-06

3.  Plitidepsin has a safe cardiac profile: a comprehensive analysis.

Authors:  Arturo Soto-Matos; Sergio Szyldergemajn; Sonia Extremera; Bernardo Miguel-Lillo; Vicente Alfaro; Cinthya Coronado; Pilar Lardelli; Elena Roy; Claudia Silvia Corrado; Carmen Kahatt
Journal:  Mar Drugs       Date:  2011-06-09       Impact factor: 6.085

4.  A common data model to assess cardiovascular hospitalization and mortality in atrial fibrillation patients using administrative claims and medical records.

Authors:  Mary P Panaccio; Gordon Cummins; Charles Wentworth; Stephan Lanes; Shannon L Reynolds; Matthew W Reynolds; Raymond Miao; Andrew Koren
Journal:  Clin Epidemiol       Date:  2015-01-12       Impact factor: 4.790

5.  The effect of apolipoprotein E gene polymorphism and Lp(a) levels on coronary artery disease with atrial fibrillation.

Authors:  Yong Li; Lei Chen; Yameng Shao; Min Zhang; Li Zhi; Yuan Lu
Journal:  J Int Med Res       Date:  2022-07       Impact factor: 1.573

6.  Trajectories of Cardiovascular Risk Factors and Incidence of Atrial Fibrillation Over a 25-Year Follow-Up: The ARIC Study (Atherosclerosis Risk in Communities).

Authors:  Faye L Norby; Elsayed Z Soliman; Lin Y Chen; Lindsay G S Bengtson; Laura R Loehr; Sunil K Agarwal; Alvaro Alonso
Journal:  Circulation       Date:  2016-08-23       Impact factor: 29.690

7.  Association of Lipid-Related Genetic Variants with the Incidence of Atrial Fibrillation: The AFGen Consortium.

Authors:  Faye L Norby; Samuel Adamsson Eryd; Maartje N Niemeijer; Lynda M Rose; Albert V Smith; Xiaoyan Yin; Sunil K Agarwal; Dan E Arking; Daniel L Chasman; Lin Y Chen; Mark Eijgelsheim; Gunnar Engström; Oscar H Franco; Jan Heeringa; George Hindy; Albert Hofman; Pamela L Lutsey; Jared W Magnani; David D McManus; Marju Orho-Melander; James S Pankow; Gull Rukh; Christina-Alexandra Schulz; André G Uitterlinden; Christine M Albert; Emelia J Benjamin; Vilmundur Gudnason; J Gustav Smith; Bruno H C Stricker; Alvaro Alonso
Journal:  PLoS One       Date:  2016-03-21       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.